Orexigen Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting

SAN DIEGO, March 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentation taking place at the American College of Cardiology (ACC) 60th Scientific Session, April 2-5.

ACC:  Ernest N. Morial Convention Center (Expo Hall), New Orleans, LA.  

Sunday, April 3:  

 

Poster Presentation

 

Abstract: 286

 

Presenter: Jorge Plutzky, MD, Director, Vascular Disease Prevention Program, Brigham and Women's Hospital, Boston, MA

 

Title: "Weight Loss, Blood Pressure, Pulse and Circadian Patterns with Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy for Obesity"

 

Time: 10:00 – 11:15 a.m. CDT

 

Location: Hall F

 

Session Title: Risk Reduction and Rehabilitation:  Role of Exercise II

 
 


 

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

CONTACT: Jay Hagan, Orexigen, +1-858-875-8600, or media, Carolyn Wang, +1-415-225-5050

Web Site: http://www.orexigen.com
 

 

 
 

Posted: March 2011

View comments

Hide
(web5)